Show Summary Details
Page of

Depression in Cancer Care 

Depression in Cancer Care
Depression in Cancer Care

Daisuke Fujisawa

and Yosuke Uchitomi

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 12 July 2020

This chapter deals with depression as a common syndrome affecting 15% to 30% of cancer patients. It impairs patients’ well-being in multiple aspects, as well as being associated with shorter survival. A wide range of physical, neurological, and mental conditions are listed as key differentials. Cancer-related fatigue is one of the common differentials. Treatment of depression should be based on severity of illness and on patients’ preferences. Good communication between medical providers and patients, and holistic care based on comprehensive needs’ assessment, which is usually done by using screening tools, are fundamental to the treatment and prevention of depression. Psychotherapy (psychological treatment) is indicated for all levels of depression severity. Pharmacotherapy (e.g., antidepressants) is an option for mild to moderate depression and is a requirement for severe depression. All treatments should be tailored based on patients’ preference, their physical condition, and access to care.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.